Solventum Corp. closed 17.76% short of its 52-week high of $96.05, which the company reached on March 26th.

Solventum has appointed former Zimmer Biomet executive Rachel Ellingson as chief strategy and corporate development officer.

Mizuho raised the firm’s price target on Solventum (SOLV) to $82 from $70 and keeps a Neutral rating on the shares following the Q4 report. The ...

Activist investor Trian Fund Management plans to push Solventum to separate more of its businesses after the company’s $4.1 ...

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

Shares of Solventum jumped Tuesday and led S&P 500 gainers intraday after medical device maker Thermo Fisher Scientific said ...

Solventum Co. (NYSE:SOLV – Get Free Report) has been assigned an average rating of “Hold” from the eleven brokerages that are currently covering the company, MarketBeat.com reports. One research ...

Solventum stock is down, even though fourth-quarter results that came in ahead of the consensus forecast on Wall Street.

Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...

Thermo Fisher Scientific agreed to pay about $4.1 billion in cash to acquire Solventum’s purification and filtration business ...

Solventum Corp., 3M’s medtech spinoff, has sold its purification and filtration business to Massachussetts-based Thermo ...

M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.